NR3C2 and cardiovascular disorder: ("empagliflozin" [Supplementary Concept] OR "dapagliflozin" [Supplementary Concept] OR "Canagliflozin/therapeutic use"[Mesh] OR "ertugliflozin" [Supplementary Concept] OR "Sodium-Glucose Transporter 2 Inhibitors/therapeutic use"[Mesh]) OR ("Spironolactone/therapeutic use"[Mesh] OR "Eplerenone/therapeutic use"[Mesh] OR "finerenone" [Supplementary Concept] OR "Mineralocorticoid Receptor Antagonists/therapeutic use"[Mesh]) AND ("Heart Failure"[Mesh] OR "Cardiovascular Diseases"[Mesh])